Back to Search Start Over

Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy.

Authors :
Ide H
Nakashima J
Kono H
Kikuchi E
Nagata H
Miyajima A
Nakagawa K
Oya M
Source :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2010 Feb; Vol. 40 (2), pp. 177-80. Date of Electronic Publication: 2009 Oct 16.
Publication Year :
2010

Abstract

The present study was undertaken to investigate the predictors in patients who received hormonal therapy (HT) for prostate-specific antigen recurrence (PSAR) after surgery. Predictors for the progression-free survival were assessed in 55 patients who received HT for PSAR after surgery. In multivariate analysis, primary Gleason grade > or =4 and PSA doubling time (PSA-DT) <6 months were independent predictors. The patients were stratified into low-risk group (Gleason grade <4 and PSA-DT > or =6), high-risk group (Gleason grade > or =4 and PSA-DT <6) and intermediate-risk group (all others). In the intermediate- and high-risk groups, progression-free survival rate was significantly higher in patients with PSA level <2 than in those with PSA level > or =2 at the initiation of HT. Primary Gleason grade > or =4 and PSA-DT <6 months are independent predictors. Patients in the intermediate- and high-risk groups may benefit from early HT for PSAR after surgery.

Details

Language :
English
ISSN :
1465-3621
Volume :
40
Issue :
2
Database :
MEDLINE
Journal :
Japanese journal of clinical oncology
Publication Type :
Academic Journal
Accession number :
19837688
Full Text :
https://doi.org/10.1093/jjco/hyp133